Hello,
I wanted to let you know about a study that is taking place at our clinic. This study is sponsored by Vanguard
Research Group and our clinic is one of the research sites helping them with this study.
What is the purpose of this study?
Schizophrenia is a condition that negatively affects people’s mental health in different ways. For example, it can
affect a person’s mood, behavior, or cognition. Cobenfy is a new FDA approved drug for the treatment of the
positive symptoms of schizophrenia. Cobenfy is different from other antipsychotics as it has a new “mechanism
of action” compared to all other antipsychotics approved from the treatment of schizophrenia at this time. Since
Cobenfy is the first medication of its drug class to be FDA approved for schizophrenia, researchers are interested
to know how this new class of antipsychotics affects those with early phase schizophrenia specifically. This
clinical trial will test if Cobenfy can help improve the positive symptoms of patients with first episode/early
phase schizophrenia, better than other antipsychotics.
To be eligible to participate, you must:
❖ Be at least 18 years or older
❖ Have a primary diagnosis of schizophrenia
❖ Have been on a stable dose of 1 antipsychotic medication for at least 8 weeks before treatment with no
dose changes within the last 4 weeks.
❖ Have started your first antipsychotic treatment within the past 5 years.
Patients who meet eligibility criteria and enroll will come into our office to receive the study drug. Once
enrolled, in-person clinic visits will occur every 1-4 weeks for about 24 weeks until the end of treatment visit,
with a final follow-up visit 28 days after you last take the study drug (no more than 13 visits total).
If you decide to participate, the study drug will be provided by/paid for by our clinic and study related
assessments will be conducted during clinic visits. You may also be compensated for your participation and be
reimbursed for any study-related travel.
Want to learn more?
If you or someone you know is interested in learning more about this research study, please feel free to contact
us by calling 312-503-9092 or emailing.
Thank you for your time and I hope to hear from you soon.
Principal Investigator: Jeffrey Rado, MD
STU00223950
